Back to Search Start Over

Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.

Authors :
Hu N
Wang F
Sun T
Xu Z
Zhang J
Bernard D
Xu S
Wang S
Kaminski M
Devata S
Phillips T
Malek SN
Source :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 15; Vol. 27 (8), pp. 2301-2313. Date of Electronic Publication: 2021 Jan 08.
Publication Year :
2021

Abstract

Purpose: On the basis of the recent discovery of mutations in Bruton tyrosine kinase ( BTK ) in follicular lymphoma, we studied their functional properties.<br />Experimental Design: We identified novel somatic BTK mutations in 7% of a combined total of 139 follicular lymphoma and 11 transformed follicular lymphoma cases, none of which had received prior treatment with B-cell receptor (BCR) targeted drugs. We reconstituted wild-type (WT) and mutant BTK into various engineered lymphoma cell lines. We measured BCR-induced signal transduction events in engineered cell lines and primary human follicular lymphoma B cells.<br />Results: We uncovered that all BTK mutants destabilized the BTK protein and some created BTK kinase-dead mutants. The phospholipase C gamma 2 (PLCγ2) is a substrate of BTK but the BTK mutants did not alter PLCγ2 phosphorylation. Instead, we discovered that BTK mutants induced an exaggerated AKT phosphorylation phenotype in anti-Ig-treated recombinant lymphoma cell lines. The short hairpin RNA-mediated knockdown of BTK expression in primary human nonmalignant lymph node-derived B cells resulted in strong anti-Ig-induced AKT activation, as did the degradation of BTK protein in cell lines using ibrutinib-based proteolysis targeting chimera. Finally, through analyses of primary human follicular lymphoma B cells carrying WT or mutant BTK , we detected elevated AKT phosphorylation following surface Ig crosslinking in all follicular lymphoma B cells, including all BTK -mutant follicular lymphoma. The augmented AKT phosphorylation following BCR crosslinking could be abrogated by pretreatment with a PI3Kδ inhibitor.<br />Conclusions: Altogether, our data uncover novel unexpected properties of follicular lymphoma-associated BTK mutations with direct implications for targeted therapy development in follicular lymphoma. See related commentary by Afaghani and Taylor, p. 2123 .<br /> (©2021 American Association for Cancer Research.)

Details

Language :
English
ISSN :
1557-3265
Volume :
27
Issue :
8
Database :
MEDLINE
Journal :
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Type :
Academic Journal
Accession number :
33419778
Full Text :
https://doi.org/10.1158/1078-0432.CCR-20-3741